Article title: Antimicrobial safety consideration in critically ill patients: part II: focused on anti-microbial toxicities
Authors: Shahbazi, F., Shojaei, L., Farvadi, F., & Kadivarian, S.
Journal: Expert Review of Clinical Pharmacology
DOI: https://doi.org/10.1080/17512433.2022.2093716
When this article was first published there were few errors present within the text which have been now corrected as below.
In Page 4 “Linezolid section” the first paragraph:
Doses more than 22 mg/kg, especially in renal failure, are recommended to avoid thrombocytopenia
The above sentence has been corrected as followed:
Doses less than 22 mg/kg, especially in renal failure, are recommended to avoid thrombocytopenia.
In Page 7 “Conclusion section” the second paragraph:
Achieving pharmacodynamic targets of beta-lactams to Cmax/MIC = 4–8 fT > 100% result in minimizing treatment failure and emerging antibiotic resistance.
The above sentence has been corrected as followed:
Achieving pharmacodynamic targets of beta-lactams to 100% fT > 4-8× MIC result in minimizing treatment failure and emerging antibiotic resistance.
In Page 7 “expert opinion section” (second column):
With the increase of pharmacodynamic targets of beta-lactams to Cmax/MIC = 4–8 fT > 100% to improve efficacy and suppression of emergence of resistance, clinicians should monitor patients for possible side effects.
The above sentence has been corrected as followed:
It should be noted that 100% fT ≥ 4 MIC has been proposed to suppress antimicrobial resistance; nevertheless, a clinical response can be achieved by 100% fT ≥ MIC.